About US
Contact us
-
Takeda's dengue vaccine efficacy slips between 12- and 18-month analysesTakeda just this month released 12-month efficacy data from a massive dengue vaccine study showing the shot was 80% effective against all dengue strains. But a newer data set shows the efficacy fell2019/11/27
-
Novartis flexes CV marketing muscles against PCSK9 rivals with MedCo dealWatch out, Amgen, Sanofi and Regeneron. Thanks to Novartis'$9.7 billionMedicines Company buyout pact, PCSK9 competition is about to get a lot more intense. But while theSwiss drugmaker will enter the2019/11/26
-
SK Biopharmaceuticals, fresh off an FDA nod, preps for $850M IPO in January: reportRight on the heels of an FDA approval for seizure medXcopri, South Korea’s SK Biopharmaceuticals is reportedly planning aninitial public offering to raise about $850 million. The company plans to lis2019/11/26
-
Roche scores FDA priority review for risdiplam, threatening Biogen and Novartis SMA medsBiogen and Novartis arebattling in the lucrative spinal muscular atrophy (SMA) field, but a third entrant could shake up the market in 2020. Roche and PTC Therapeutics’risdiplamjustpicked upan FDA pr2019/11/25
-
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's makerDriven by a landmarkcardiovascular outcomes trial that could spell blockbuster sales for its fish-oil derivative, Vascepa, Amarin has been a darling for pharma M&A speculators. Now, after Novarti2019/11/25
-
Sanofi strategy exec Mansuri jumps ship ahead of new CEO's big revealNew Sanofi CEO Paul Hudson is days away from unveiling his plans for the French drugmaker, but the company's top strategy executive won't wait that long to leave. Muzammil Mansuri, Sanofi’s executive2019/11/22
-
FiercePharmaAsia—Novartis' Shanghai R&D revamp; BeiGene's Imbruvica rival; Shionogi's antibioticNovartis is refocusing its Shanghai R&D operation to drug development instead ofearly drug discovery. BeiGene nabbed the first FDA nod for a China-discovered cancer drug, a challenger to Johnson2019/11/22
-
SK Life Science plots 2020 launch for now-approved seizure drug XcopriSK Life Science has set out to transform itself into a commercial biopharmacompany, and with its seizure medXcopri now armed with an FDA approval,thedrugmakerisgearing up for its first-ever launch. F2019/11/21
-
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MSLate last year, Bristol-Myers Squibb made a last-minute revision of its offer to buy Celgene: Instead of paying $57 per share in cash and a one-to-one share trade, BMS offered $50, plus one BMS share2019/11/21
-
Antitrust reviews delay Roche's Spark deal further, but where are investors?As expected, Roche and Spark Therapeutics have once again delayed their tender offer for the $4.3 billion acquisition. “[T]o provide additional time for the U.S. Federal Trade Commission (FTC) and th2019/11/20